Paludisme à Plasmodium vivax

This condition is caused by a protozoal parasite that functions as a distinct human pathogen ^[1]. It is recognized as the predominant agent responsible for recurrent malaria infections across diverse geographic zones ^[1]. Modern clinical assessments have reclassified its historical perception, confirming that it actively drives significant morbidity and fatality rates comparable to other major malaria species ^[2].

Infections frequently involve haematological alterations, including marked declines in haemoglobin concentration that require careful monitoring during therapeutic courses ^[4][5]. Severe manifestations commonly encompass acute respiratory distress syndrome and pronounced splenomegaly, both of which correlate with elevated case fatality ^[2][1]. Patients may also experience gastrointestinal disturbances such as vomiting, anorexia, or diarrhoea, particularly during multi-day treatment protocols ^[5]. Clinical indicators like reduced baseline haemoglobin, lower body temperature, and diminished oxygen saturation significantly predict adverse outcomes in complicated presentations ^[2].

Malaria constitutes a major global public health challenge, predominantly caused by Plasmodium falciparum and Plasmodium vivax, and accounts for nearly half a million deaths each year ^[3]. The disease burden is actively increasing in several African and South American regions, with 2021 data reporting an estimated 247 million cases and 619,000 fatalities across 84 endemic nations ^[4].

The disease is propagated by Anopheles mosquito vectors, which continue to develop physiological and behavioural resistance to insecticides, thereby complicating efforts to interrupt transmission and control spread ^[4].

Strategic mitigation emphasizes the systematic deployment of intermittent preventive therapies targeting pregnant individuals and infants, supplemented by seasonal chemoprevention frameworks ^[3]. International health guidelines additionally endorse the integration of pre-erythrocytic immunizations to further diminish community transmission and illness severity ^[3]. Long-term elimination objectives depend on synchronized mass drug administration programs, optimized vector management strategies, and sustained pharmaceutical innovation to overcome existing therapeutic barriers ^[3].

1. 1 Wikipedia contributors. Plasmodium vivax [Internet]. Wikipedia. cited 3 Sept 2026. Available from: https://en.wikipedia.org/wiki/Plasmodium_vivax
2. 2 Val F et al. Respiratory Complications of Plasmodium vivax Malaria: Systematic Review and Meta-Analysis. Am J Trop Med Hyg. 2017 Sep. PMID: 28722625. doi: 10.4269/ajtmh.17-0131. PubMed: https://pubmed.ncbi.nlm.nih.gov/28722625/
3. 3 Poespoprodjo JR et al. Malaria. Lancet. 2023 Dec 16. PMID: 37924827. doi: 10.1016/S0140-6736(23)01249-7. PubMed: https://pubmed.ncbi.nlm.nih.gov/37924827/
4. 4 Rajasekhar M et al. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2024 Feb. PMID: 37748497. doi: 10.1016/S1473-3099(23)00431-0. PubMed: https://pubmed.ncbi.nlm.nih.gov/37748497/
5. 5 Commons RJ et al. Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis. Lancet Child Adolesc Health. 2024 Nov. PMID: 39332427. doi: 10.1016/S2352-4642(24)00210-4. PubMed: https://pubmed.ncbi.nlm.nih.gov/39332427/